Clinical Research Papers:
The role of systemic chemotherapy and multidisciplinary management in improving the overall survival of patients with metastatic squamous cell carcinoma of the anal canal
Metrics: PDF 1927 views | HTML 2355 views | ?
Cathy Eng1, George J. Chang2, Y. Nancy You2, Prajnan Das3, Miguel Rodriguez-Bigas2, Yan Xing2, Jean-Nicolas Vauthey2, Jane E. Rogers4, Aki Ohinata1, Priyanka Pathak1, Salil Sethi1, Jonathan K. Phillips1, Christopher H. Crane3, Robert A. Wolff1
1Department of Gastrointestinal Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030
2Department of Surgical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030
3Department of Radiation Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030
4Division of Pharmacy, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030
Cathy Eng, e-mail: email@example.com
Received: October 01, 2014 Accepted: October 02, 2014 Published: November 14, 2014
Metastatic squamous cell carcinoma (SCCA) of the anal canal is a rare malignancy for which no standard treatment algorithm exists. To determine the best approach, all patients diagnosed with metastatic SCCA of the anal canal treated at a single institution were evaluated for choice of chemotherapy and treatment outcome. A retrospective study from January 2000 to May 2012 was conducted. Electronic medical records were reviewed for diagnosis of metastatic SCCA of the anal canal. All patients were treatment naïve for metastatic disease and completed all radiographic imaging at our institution. The purpose of this study was to evaluate outcomes among patients who received systemic chemotherapy and if appropriate were referred for multidisciplinary intervention (e.g., surgery, radiofrequency ablation, etc.). Seventy-seven patients fulfilled eligibility criteria. Forty-two patients (55%) received 5-fluorouracil (5-FU) + cisplatin (PF); 24 patients (31%) received carboplatin + paclitaxel (CP); 11 patients (14%) received an alternative regimen. After a median follow-up of 42 months, the median progression-free survival (PFS) for all patients was 7 months; the median overall survival (OS) was 22 months. Thirty-three patients (43%) underwent multidisciplinary management for metastatic disease resulting in a median PFS of 16 months (95% CI: 9·2 -22·8) and median OS of 53 months (95% CI: 28·3 – 77·6). Systemic chemotherapy provides durable survival for patients with surgically unresectable metastatic SCCA of the anal canal. Multidisciplinary management for select patients with metastatic disease effectively improves survival and should be considered whenever possible.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.